Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Second-Generation Antidepressants for Treating Adult Depression—An Update

Slide: 20 of 28

Overall Comparative Harms of Second-Generation Antidepressants for Adults With Major Depressive Disorder

Overall there is high-strength evidence that the rates of adverse events were similar among second-generation antidepressants, though incidence of specific adverse effects differed across antidepressants and will be addressed in the following slides. Research on comparative harms for the different formulations of second-generation antidepressants found that there was moderate-strength evidence that there were no differences in harms between fluoxetine daily and fluoxetine weekly or between venlafaxine immediate release and venlafaxine extended release.